



## ANNUAL MEETING PROGRAMME

**Thursday 30 September 2021**

09.30-10.00	<b>POSTER VIEWING / SPONSOR ENGAGEMENT, NETWORKING</b> <i>(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)</i>
10.00-10.10	<b>Opening of the Annual HAI Meeting – Prof. James O’Donnell, President</b>
	<b>SESSION 1 – Oral Presentations 6 x 10 minute Presentations</b> <b>Chairpersons: Prof. James O’Donnell and Dr Su Maung</b>
10.10-10.20	CHD4 LOSS IN ACUTE MYELOID LEUKAEMIA GIVES RISE TO INCREASED DNA DAMAGE REPAIR DEFECTS AND ALTERED CELL CYCLE PROGRESSION <b>Deirdre Venney, QUB</b>
10.20-10.30	RECREATING THE BONE MARROW MICROENVIRONMENT TO MODEL LEUKEMIC STEM CELL QUIESCENCE <b>Eimear O’Reilly, NUIG</b>
10.30-10.40	COVID-19 CONVALESCENT PLASMA, THE NORTHERN IRELAND BTS EXPERIENCE <b>Andrea Piccin, NIBTS</b>
10.40-10.50	VENETOCLAX AND EPIGENETIC MODIFIERS: PROMISING NOVEL COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA <b>Lyndsay Flanagan, RCSI</b>
10.50-11.00	CHIMERIC ANTIGEN RECEPTOR T-CELL (CART) THERAPY IN IRISH CHILDREN WITH RELAPSED/REFRACTORY PAEDIATRIC B-ACUTE LYMPHOBLASTIC LEUKAEMIA (B-ALL) <b>Valerie Broderick, CHI at Crumlin</b>
11.00-11.10	NOVEL INSIGHTS INTO THE ROLE OF VON WILLEBRAND FACTOR IN THE PATHOGENESIS OF PAEDIATRIC SICKLE CELL DISEASE <b>Helen Fogarty, RCSI</b>
11.10-11.20	NATURAL HISTORY OF VACCINE-INDUCED THROMBOCYTOPENIA AND THROMBOSIS (VITT) IN IRELAND <b>Dawn Swan, St James’s Hospital, Dublin</b>
11.20-11.30	INVESTIGATION OF SAMPLES REFERRED FOR IMMUNE HAEMOLYTIC ANAEMIA: TWO CASES REFERRED TO THE NATIONAL BLOOD CENTRE <b>Eileen Ryan, IBTS</b>
11.30-11.40	DETERMINING EFFECTIVE DRUG COMBINATIONS FOR PAEDIATRIC ACUTE MYELOID LEUKAEMIA <b>Áine McGill, Patrick G Johnston Centre for Cancer Research, CCRCB</b>
11.40-11.50	IMPACT OF P53 DISRUPTION ON MANTLE CELL LYMPHOMA (MCL) TREATMENT OUTCOME <b>Rehman Faryal, Mater Misericordiae University Hospital</b>
11.50-12.00	USE OF CALCULATED GLOBULIN FOR DEMAND TARGETING OF MULTIPLE MYELOMA TESTING <b>Aisling O’Brien, Cork University Hospital</b>
12.00-12.45	<b>STATE OF THE ART LECTURE: Introduced by: Dr Barry Kevane</b>  <i>Professor Jo Howard, Consultant Haematologist//Honorary Professor in Haemoglobinopathies Guy’s and St Thomas’ Hospital, London</i>
12.45-13.30	<b>POSTER VIEWING / SPONSOR ENGAGEMENT, NETWORKING</b> <i>(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)</i>



**ANNUAL MEETING PROGRAMME**

**Thursday 30 September 2021**

13.30	Session 2: Chairpersons: Dr Siobhan Glavey & Prof. Feargal McNicholl
13.30-14.15	STATE OF THE ART LECTURE: Introduced by: Dr Siobhan Glavey  <i>Coagulopathy &amp; COVID-19: Clinical Challenges and Therapeutic Opportunities</i> <i>Dr Barry Kevane, Consultant Haematologist</i> <i>Mater Misericordiae University Hospital</i>
14.15 -14.25	CD49D EXPRESSION IN CLL IS STRONGLY ASSOCIATED WITH NOTCH1 MUTATIONS AND REDUCED TIME TO FIRST-TREATMENT <b>Aidan Kelly, Trinity St. James' Cancer Institute</b>
14.25-14.35	EZH2 LOSS DYSREGULATES CELLULAR METABOLISM AND SENSITIZES AML CELLS TO BCL2 INHIBITION <b>Dr Luke Jones, Systems Biology Ireland, UCD</b>
14.35-14.45	THE BURDEN OF ANAEMIA AND EXTENT OF SCREENING FOR IRON, B12, AND FOLATE DEFICIENCY AMONG PATIENTS IN THE IRISH HEALTH SYSTEM: A COHORT STUDY <b>Conor Clancy, University of Limerick</b>
14.45-14.55	SINGLE CELL TRANSCRIPTOMICS REVEALED MOLECULAR ALTERATIONS IN AML CELL CLUSTERS RELEVANT TO REFRACTORY DISEASE AT RELAPSE <b>Alessandra Conforte, NUIG</b>
14.55-15.05	OUTCOME OF PATIENTS DIAGNOSED AND TREATED WITH ACUTE LYMPHOBLASTIC LEUKAEMIA IN ST JAMES HOSPITAL: A SINGLE INSTITUTION STUDY <b>Bryan Dillon, St. James's Hospital</b>
15.05-15.15	METABOLIC CHANGES IN VENETOCLAX RESISTANCE ARE DETERMINED BY DIFFERENTIATION STATE IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA <b>Andrew Roe, RCSI</b>
15.15-16.00	STATE OF THE ART LECTURE – Introduced by: Prof. Feargal McNicholl  <i>Dr Nicholas Cunningham, Consultant Haematologist</i> <i>Belfast City Hospital</i>
16.00	Day 1 Closing Comments <b>Professor James O'Donnell, President</b>

This meeting is kindly sponsored by: AbbVie, Accord Healthcare, Amgen, Astellas, Bristol-Myers Squibb, Gilead, Incyte, Janssen, Jazz Pharma, Leo Pharma, Mallinckrodt Pharmaceuticals, Novartis, ONCOassist, Pfizer Hospital, Pfizer Oncology, Roche and Takeda  
*(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)*



<b>ANNUAL MEETING PROGRAMME</b>	
<b>Friday 1<sup>st</sup> October 2021</b>	
09.30-10.00	POSTER VIEWING / SPONSOR ENGAGEMENT, NETWORKING <i>(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)</i>
10.00-10.05	<b>Opening of Day 2 - Annual HAI Meeting – Prof. James O’Donnell, President</b>
10.05	<b>SESSION 3 – Oral Presentations 7 x 10 minute Presentations</b> <b>Chairpersons: Dr Andrea Malone and Dr Barry Kevane</b>
10.05-10.15	COAGULATION-CANCER CROSSTALK; VON WILLEBRAND FACTOR CONTRIBUTES TO PRO-INVASIVE AND PRO-ANGIOGENIC PROPERTIES IN BREAST CANCER CELLS <b>Sean Patmore, RCSI</b>
10.15-10.25	A ROLE FOR MUC1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA <b>Aidan Kelly, Trinity St. James' Cancer Institute</b>
10.25-10.35	METABOLIC REPROGRAMMING IS ESSENTIAL FOR MYELOID CELL PROCOAGULANT AND ANTIFIBRINOLYTIC ACTIVITY <b>Aisling Rehill, RCSI</b>
10.35-10.45	GENERATION OF NATURAL KILLER CELL MIMIC NANOPARTICLES TO TARGET TUMOUR CELLS <b>Hojjat Alizadeh Zeinabad, NUIG</b>
10.45-10.55	USE OF THERAPEUTIC PLASMA EXCHANGE (TPE) TO TREAT ACUTE MULTIPLE SCLEROSIS (MS) RELAPSE IN PREGNANCY <b>Lorraine Lester, IBTS</b>
10.55-11.05	FRAILTY IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION: DEVELOPING TOOLS TO IDENTIFY VULNERABILITY AND IMPROVE SURVIVORSHIP <b>Kate Banks, St James’s Hospital</b>
11.05-11.15	ACTIVATED PROTEIN C REGULATES COLITOGENIC T CELL ACTIVITY <b>Gemma Leon, RCSI</b>
11.15-11.30	<b>Novartis Fellowship Update – 2019 Winner</b> <b>Dr Luke Jones, Systems Biology Ireland, UCD</b>
11.30-12.15	STATE OF THE ART LECTURE – Introduced by: Dr Andrea Malone  <i>“CAR T cell therapy for paediatric ALL- where to next?”</i> <b>Prof. Persis Amrolia</b> <b>Professor of Transplantation Immunology UCL Great Ormond St Institute of Child Health and Director of BMT Great Ormond St Children’s Hospital</b>
12.15-13.00	POSTER VIEWING / SPONSOR ENGAGEMENT, NETWORKING <i>(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)</i>
13.00-14.00	<b>PRESIDENT’S SYMPOSIUM – Chairpersons: Professor James O’Donnell and Professor Feargal McNicholl</b>
13.00-13.15	HUWE1 orchestrates DNA Repair in response to Replicative Stress in Multiple Myeloma <b>Jonathan Morgan, QUB</b>
13.15-13.30	PERSISTENT ENDOTHELIOPATHY IN THE PATHOGENESIS OF LONG COVID SYNDROME <b>Helen Fogarty, RCSI</b>
13.30-13.45	TC BUSTER TRANSPOSON ENGINEERED CLL-1 CAR-NK CELLS EFFICIENTLY TARGET ACUTE MYELOID LEUKAEMIA <b>Mark Gurney, NUIG</b>
13.45-14.00	CAR T CELL THERAPY FOR HIGH GRADE B CELL LYMPHOMA, IRISH PATIENTS AVAILING OF THERAPY IN KING COLLEGE HOSPITAL AND UNIVERSITY COLLEGE HOSPITAL, LONDON <b>Feargal McGlynn, St James’s Hospital</b>



**ANNUAL MEETING PROGRAMME**

**Friday 1<sup>st</sup> October 2021**

<b>14.00-15.00</b>	<b>LIAM O'CONNELL LECTURE - Introduced by: Dr Jamie O'Sullivan</b>  <i>Professor Christophe Dubois</i> <i>Professor of Cell Biology, Aix Marseille University, Marseille</i>
<b>15.00</b>	<b>CLOSE OF CONFERENCE AND AWARDING OF EDUCATIONAL AWARDS</b>

This meeting is kindly sponsored by: AbbVie, Accord Healthcare, Amgen, Astellas, Bristol-Myers Squibb, Gilead, Incyte, Janssen, Jazz Pharma, Leo Pharma, Mallinckrodt Pharmaceuticals, Novartis, ONCOassist, Pfizer Hospital, Pfizer Oncology, Roche and Takeda  
*(All sponsors have supported the overall event by being acknowledged with the relevant company logo on the platform and holding exhibition space. Sponsors have had no input into the Agenda, speaker selection or content of this meeting)*